Effect of Pemafibrate on the Lipid Profile, Liver Function, and Liver Fibrosis Among Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
Mona HassanHasan Al-ObaidiMegan KarrickNooraldin MerzaYusuf NawrasOmar SaabAhmed Dheyaa Al-ObaidiFatima MerzaHashim Talib HashimKhalid Al ZubaidiDaniah Al-SabbaghRand MatbachiZainab NooriHajra Amatul-RaheemSarmad MansurOmer Al NajafiMarwah AlgodiTamarah Al HamdanyAbdallah KobeissyPublished in: Gastroenterology research (2024)
Pemafibrate, with its enhanced efficacy and safety profile, presents as a pivotal agent in MASLD/MASH treatment. Its lipid-regulating properties, coupled with its beneficial effects on liver inflammation markers, position it as a potentially invaluable therapeutic option.